- Title
- TREATMENT UTILIZATION AND ASSOCIATED FACTORS IN PATIENTS WITH PRIMARY ADVANCED OR FIRST RECURRENT ENDOMETRIAL CANCER AFTER IMMUNOTHERAPY COMBINATION APPROVAL IN THE UNITED STATES
- Creators
- Leslie M. Randall - Virginia Cancer InstituteSolomon Lubinga - GlaxoSmithKline (United States)Qin Shen - GlaxoSmithKline (United States)Jean HurteauMagdalena Zajac - GlaxoSmithKline Research & Development Limited (United Kingdom)Ramya Peter - GlaxoSmithKline (United States)Matthias Hunger - Cardiovascular Center FrankfurtJaya Paranilam - ICON PLC (Ireland)John Farley
- Publication Details
- International journal of gynecological cancer, Vol.36(10), p.105430
- Identifiers
- 991006323761602656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
TREATMENT UTILIZATION AND ASSOCIATED FACTORS IN PATIENTS WITH PRIMARY ADVANCED OR FIRST RECURRENT ENDOMETRIAL CANCER AFTER IMMUNOTHERAPY COMBINATION APPROVAL IN THE UNITED STATES
International journal of gynecological cancer, Vol.36(10), p.105430
10/2026
Metrics
2 Record Views